Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Seres Therapeutics
Biotech
Ikena and Inmagene choose combined CEO—Chutes & Ladders
Ikena and Inmagene choose combined CEO. Galapagos expands executive island. Trogenix trots out new clinical leaders.
Darren Incorvaia
,
Zoey Becker
Jul 25, 2025 8:30am
Seres slims R&D, staff to focus on approved microbiome drug
Nov 2, 2023 12:22pm
Leaps by Bayer chief jumps to Bayer, too—Chutes & Ladders
Aug 25, 2023 9:30am
FDA mulls approving first oral microbiome therapy from Seres
Oct 26, 2022 9:55am
Equipped with new safety data, Seres eyes FDA approval
Jun 7, 2022 7:00am
Seres Therapeutics' microbiome therapy flops against placebo
Jul 22, 2021 7:30am
